CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer.

ABSTRACT: According to cancer statistics reported in 2020, breast cancer constitutes 30% of new cancer cases diagnosed in American women. Histological markers of breast cancer are expressions of the estrogen receptor (ER), the progesterone receptor (PR), and human epidermal growth factor receptor (HER)-2. Up to 80% of breast cancers are grouped as ER-positive, which implies a crucial role for estrogen in breast cancer development. Therefore, identifying potential therapeutic targets and investigating their downstream pathways and networks are extremely important for drug development in these patients. Through high-throughput technology and bioinformatics screening, we revealed that coiled-coil domain-containing protein 167 (CCDC167) was upregulated in different types of tumors; however, the role of

SUBMITTER: Chen PS 

PROVIDER: S-EPMC7906182 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature